Related Experiment Video
Updated: Jun 10, 2026
07:55
Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
Published on: April 11, 2018
Guidelines for the management of soft tissue sarcomas
Robert Grimer1, Ian Judson, David Peake
1Royal Orthopaedic Hospital NHS Trust, Birmingham B31 2AP, UK.
Sarcoma
|July 17, 2010
Summary
UK sarcoma specialists developed guidelines for soft tissue sarcoma care, emphasizing multidisciplinary teams and tailored treatments like surgery, radiotherapy, and chemotherapy. Regular follow-up and specific management for metastatic disease are crucial.
Area of Science:
- Oncology
- Surgical Oncology
- Medical Guidelines
Background:
- Soft tissue sarcomas require specialized multidisciplinary care.
- Existing international guidelines (ESMO, NCCN) and UK-specific guidance (NICE) inform current practice.
- Cancer treatment evolves, necessitating regular guideline updates.
Purpose of the Study:
- To establish UK-specific guidelines for the multidisciplinary care of soft tissue sarcoma patients.
- To adapt international best practices to UK clinical settings.
- To provide a framework for managing various sarcoma types, including limb, retroperitoneal, and uterine sarcomas.
Main Methods:
- Consensus meeting of UK sarcoma specialists.
- Adaptation of European Society of Medical Oncology (ESMO) and National Comprehensive Cancer Network (NCCN) guidelines.
- Consideration of National Institute for Health and Clinical Excellence (NICE) guidance and technology appraisals.
Main Results:
- Referral to specialist diagnostic centers and management by multidisciplinary teams are essential for suspected soft tissue sarcomas.
- Standard treatment for high-grade limb sarcomas involves surgical excision and post-operative radiotherapy; amputation may be necessary.
- Pre-operative therapy, isolated limb perfusion, and adjuvant chemotherapy are considered in specific cases.
- First-line metastatic disease treatment typically involves single-agent doxorubicin, with ifosfamide as an alternative.
- Second-line options include ifosfamide, dacarbazine, trabectedin, and gemcitabine + docetaxel combinations.
- Surgical resection of local recurrence and pulmonary metastases should be considered.
Conclusions:
- These guidelines provide a framework for optimal soft tissue sarcoma management in the UK.
- Multidisciplinary team involvement is critical throughout patient care.
- Treatment strategies should be individualized based on tumor characteristics and patient factors.
- Guidelines require regular updates to reflect advancements in sarcoma treatment.
